Roivant Sciences (ROIV) EBITDA Margin Growth (5y) (2025 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) EBITDA Margin Growth (5y) (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.66 Bn | 197.67 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.63 Bn | 74.64 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.60 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.55 Bn | 49.41 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.71 Bn | 992.69 Mn |
| 8 | Biogen | 31.26 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn |
| 10 | Insmed | 28.19 Bn | 27.03 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.34 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Sep 30, 2025 | -766,060.00 |
| Jun 30, 2025 | -586,780.00 |